Enbrel was initially launched in November 1998, and in addition to psoriatic arthritis, it is also approved for the following indications: reducing the signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis (RA), and for reducing signs and symptoms in patients four years of age and older with moderately to severely active polyarticular-course juvenile rheumatoid arthritis.